Slide 1 Slide 2 19 102 patients, 51 countries, 1139 centers Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the…

1. Ivabradine inORIGINAL ARTICLEStable Coronary Artery Disease withoutClinical Heart FailureKim Fox et al,NEJM,Aug 31,2014 2. Does it Signify the benefit of Ivabradineor…

Slide 1 Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med. 2014 August 31. DOI:10.1056/NEJMoa1406430. Slide 2 Ivabradine n=654 (3.03% PY) Placebo…

Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med. 2014 August 31. DOI:10.1056/NEJMoa1406430. Ivabradine n=654 (3.03% PY) Placebo n=611 (2.82%…

A step further in the management of stable coronary patients with ivabradine Rationale RATIONALE In CAD patients, high heart rate is associated with higher mortality1 CAD…

Committees Pierluigi Tricoci, Denise M. D’Andrea, Paul A. Gurbel, Marina Cuchel, Brion M. Winston, Robert Schott, Robert J. Weiss, Henry E. Paez, Michael A. Blazing, Louis…

19 102 patients, 51 countries, 1139 centers Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG…

Committees Pierluigi Tricoci, Denise M. D’Andrea, Paul A. Gurbel, Marina Cuchel, Brion M. Winston, Robert Schott, Robert J. Weiss, Henry E. Paez, Michael A. Blazing, Louis…

Nuevos fármacos para la prevención del ictus aterotrombótico: una de cal y otra de arena 3 Torcetrapib o cómo elevar el colesterol HDL sin evitar la progresión de la…

Regression of atherosclerosis and related CV diseases Jean-Claude Tardif MD, FRCPC, FACC, FCAHS Director, MHI Research Center Professor of Medicine UdeM Endowed Research…